Important to support our results is the demonstration by Yilmanz et al. that nondiabetic CKD patients at stages 3-4, not using erythropoietin-based agents, showed a reduction of the flow-mediated dilatation for hemoglobin levels higher that 11.6 g/dL. This evidence concerns the gene EPO and chronic kidney disease.